Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tamoxifen + tegafur-uracil
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Tamoxifen + tegafur-uracil is an oral combination therapy used primarily in the treatment of estrogen receptor (ER)-positive early and advanced breast cancer. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an antagonist of the estrogen receptor in breast tissue, thereby inhibiting tumor growth driven by estrogen signaling. Tegafur-uracil (UFT) is a fixed-dose combination of tegafur, a prodrug of 5-fluorouracil (5-FU), and uracil, which inhibits dihydropyrimidine dehydrogenase to increase 5-FU bioavailability. This combination provides cytotoxic antitumor activity by interfering with DNA synthesis in rapidly dividing cells. The regimen has demonstrated non-inferiority to standard cyclophosphamide-methotrexate-fluorouracil regimens for ER-positive node-positive early breast cancer and offers improved tolerability with fewer hematologic and gastrointestinal side effects compared to traditional chemotherapy[1][4]. It is widely used as adjuvant therapy in Japan.
- Brand names
- UftoralOrzel
- Other names
- tamoxifen + UFTtamoxifen + uracil-tegafur
02
Targets
ER (Estrogen receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on tamoxifen + tegafur-uracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tamoxifen + tegafur-uracil.